Forward Science issued the following announcement on Dec. 19.
Forward Science received FDA Clearance for OrapeuticTM, a non-opioid oral pain relief gel. Forward Science is a MedTech company that operates R&D, its quality system, manufacturing, sales and support all from its Worldwide headquarters in Houston, TX. The company’s flagship product, OralID, received FDA Clearance in March of 2013 and has since revolutionized the way clinicians screen for early stage oral cancer. In 2016 the company launched SalivaMAX in efforts to provide patients with a clinically proven option to mitigate the effects of xerostomia and mucositis. Orapeutic, the company’s third FDA cleared product, has been developed to fight the current opioid epidemic that the healthcare industry is facing today.
“We are proud of our previously released products and their impact on the healthcare industry, but our R&D team is always striving to develop products that meet market demands,” shares Forward Science co-founder and Chief Technology Officer Brian Pikkula, PhD. “With the success of our previous product launches, we have become the industry’s leader of innovative solutions in oral healthcare. We are thrilled to receive FDA clearance for Orapeutic and are looking forward to hearing from clinicians as to how this product impacts their patients.”
Dentists and oral surgeons are by far the majority of prescribers for opioids to people ages 10-19. This is a critical age range in which the still developing brain is particularly susceptible to addiction. (Journal of American Medical Association, 2011). With the recent concerns surrounding opioid prescription in the dental industry, Forward Science has been working on a non-drug option to manage oral pain, and Orapeutic will do just that. “With the opioid epidemic resulting in countless lives lost and impacted, we wanted to play a role in providing a solution for oral pain relief without the risk of addiction. We are excited to have a product that is all-natural and non-opioid, but still provides patients with adequate pain relief. We truly believe this is a product that can change lives!”
Forward Science expects to launch Orapeutic in early 2020 to complement their current therapeutic options for healthcare providers.
FDA Indications for Orapeutic:
OrapeuticTM Oral Pain Gel manages the pain of oral wounds, mouth sores, injuries and ulcers of the oral mucosa. It adheres to the oral tissue and forms a protective barrier between the wound and further prevents irritation and contamination. Orapeutic Oral Pain Gel also maintains a moist wound environment.
About Forward Science
Forward Science is a privately held MedTech company based in Houston, Texas. OralID, Forward Science’s flagship product, is an award-winning oral cancer screening device that allows clinicians to visualize abnormalities that may not be seen under traditional white light examinations. With the success of OralID, Forward Science continued to focus on moving science forward in the oral healthcare industry by launching advanced diagnostic testing products (CytID, hpvID, phID, PathID) along with treatment options (SalivaMAX and SalivaCAINE). In addition to developing proprietary, state-of-the-art products, Forward Science has partnered with industry leaders to provide new and effective solutions to the dental community. Forward Science designs, develops, and manufactures their products in-house, ensuring the highest quality of standards coupled with superior customer service. Forward Science has quickly evolved into the industry leader for providing oral healthcare products worldwide.
Original source can be found here.
